Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SGN-CD123A |
| Synonyms | |
| Therapy Description |
SGN-CD123A is an antibody-drug conjugate comprising a CD123 (IL3RA)-targeted antibody linked to pyrrolobenzodiazepine dimers, which delivers the DNA cross-linking agent to CD123 (IL3RA)-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 29142066). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SGN-CD123A | SGNCD123A|SGN CD123A | CD123 (IL3RA) Antibody 14 | SGN-CD123A is an antibody-drug conjugate comprising a CD123 (IL3RA)-targeted antibody linked to pyrrolobenzodiazepine dimers, which delivers the DNA cross-linking agent to CD123 (IL3RA)-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 29142066). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02848248 | Phase I | SGN-CD123A | A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia | Terminated | USA | 0 |